Your selection
NoneFilter by content type
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference
November 29, 2022 - … Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early … Disease (Ctad) Conference Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early … global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational …
Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)
July 29, 2021 - … AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401) Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401) July 29, 2021 News Release General Eisai … Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label …
Eisai Initiates BLA Submission of Data for Lecanemab in China
December 22, 2022 - … Eisai Initiates BLA Submission of Data for Lecanemab in China Eisai Initiates BLA Submission of Data for Lecanemab in China December 22, 2022 News Release General … Medical Products Administration (NMPA) of China for lecanemab (development code: BAN2401), an investigational …
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
April 19, 2021 - … Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early … Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early … Research and Therapy April 19, 2021 News Release General Lecanemab Phase 3 Clarity AD Clinical Trial Completed …
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting
March 30, 2023 - … Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting … from the results of Eisai’s Phase 3 Clarity AD study of lecanemab (generic name, U.S. brand name: LEQEMBI™), an …
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
March 30, 2023 - … Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals … Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals … study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to …
Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship to Clinical Outcomes and Dosing Regimens - Presented at AD/PD™ 2022 Annual Meeting
March 21, 2022 - … Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers … Presented at AD/PD™ 2022 Annual Meeting Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers … "Biogen") announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Aβ) …
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
September 27, 2021 - … to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the … to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the … Approval Pathway September 27, 2021 News Release General LECANEMAB IS AN ANTI-AMYLOID BETA (Aβ) PROTOFIBRIL ANTIBODY …
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
May 15, 2023 - … Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease May 15, … Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an …
EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
May 9, 2022 - … TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE … TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE UNDER THE … anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive …
Pagination
- Page 1
- Next page ››